

BioMed Israel 2026 ABSTRACT

Company name: Everly Bio Website: www.everly.bio

CTO & COO name: Michal Gilon Ohev-Zion

CATEGORY: Medical Devices

SESSION: The Device Is No Longer a Device: Convergence in Medical Technology.

Title: *Everly Bio – How AI with molecular insights can change the fertility journey*

- **Executive Summary / Investment Rational**

Infertility affects 1 in 6 couples globally, with male factors contributing to 50% of cases. Everly Bio is transforming this \$40B+ market by moving from "observational" sperm analysis to "predictive" reproductive diagnostics. Addressing the male factor is a women's health issue. Reducing failed IVF cycles saves unnecessary rounds of hormones and invasive procedures.

- **Core Technology**

Everly Bio's platform represents the convergence of AI-driven computational biology and liquid biopsy. By analyzing non-invasively molecular signatures within seminal fluid, we identify high-potential markers invisible to traditional microscopy. This "intelligence layer" transforms raw biological data into a predictive success score, providing a non-invasive, data-driven alternative to subjective morphology and invasive sperm assessment.

- **Product Profile/Pipeline**

Our flagship product is an AI-driven sperm assessment platform currently entering US clinical trials through a CLIA lab infrastructure. Our innovation pipeline features a Point-of-Care transition of this diagnostic, alongside a non-invasive embryo selection tool. Ultimately, we are leveraging the molecular markers identified by our platform to develop targeted therapeutics, closing the loop between advanced diagnostics and personalized fertility treatment.

- **Business Strategy**

Everly Bio employs a "Service-to-Product" model to maximize early revenue while scaling up the technology. We generate near-term revenue through a US CLIA lab (LDT model), leveraging this real-world data to refine our AI. Long-term, we are developing a Point-of-Care device for global distribution, creating recurring revenue through proprietary assay and AI algorithm.

- **What's Next?**

Throughout 2026, Everly Bio will focus on initiating US trials to validate our predictive model on US population. Establish a US CLIA lab for commercial launch. Simultaneously, we are finalizing strategic co-development agreements with major U.S. diagnostic partners to accelerate the transition of our technology into a localized Point-of-Care solution for fertility clinics.